Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease.
Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM; Synaptic Health Endpoints Working Group. Colom-Cadena M, et al. Alzheimers Res Ther. 2020 Mar 2;12(1):21. doi: 10.1186/s13195-020-00588-4. Alzheimers Res Ther. 2020. PMID: 32122400 Free PMC article. Review.
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter.
LaBarbera KM, Sheline YI, Izzo NJ, Yuede CM, Waybright L, Yurko R, Edwards HM, Gardiner WD, Blennow K, Zetterberg H, Börjesson-Hanson A, Morgan R, Davis CS, Guttendorf RJ, Schneider LS, DeKosky S, LeVine H 3rd, Grundman M, Caggiano AO, Cirrito JR, Catalano SM, Hamby ME. LaBarbera KM, et al. Among authors: caggiano ao. Transl Neurodegener. 2023 May 12;12(1):24. doi: 10.1186/s40035-023-00358-w. Transl Neurodegener. 2023. PMID: 37173791 Free PMC article. Clinical Trial. No abstract available.
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer's disease.
Colom-Cadena M, Toombs J, Simzer E, Holt K, McGeachan R, Tulloch J, Jackson RJ, Catterson JH, Spires-Jones MP, Rose J, Waybright L, Caggiano AO, King D, Gobbo F, Davies C, Hooley M, Dunnett S, Tempelaar R, Meftah S, Tzioras M, Hamby ME, Izzo NJ, Catalano SM, Durrant CS, Smith C, Dando O, Spires-Jones TL. Colom-Cadena M, et al. Among authors: caggiano ao. Acta Neuropathol. 2024 Feb 6;147(1):32. doi: 10.1007/s00401-023-02679-6. Acta Neuropathol. 2024. PMID: 38319380 Free PMC article.
A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse.
Greenberg BM, Bowen JD, Alvarez E, Rodriguez M, Caggiano AO, Warrington AE, Zhao P, Eisen A. Greenberg BM, et al. Among authors: caggiano ao. Mult Scler J Exp Transl Clin. 2022 Apr 26;8(2):20552173221091475. doi: 10.1177/20552173221091475. eCollection 2022 Apr-Jun. Mult Scler J Exp Transl Clin. 2022. PMID: 35496758 Free PMC article.
Chondroitinase improves anatomical and functional outcomes after primate spinal cord injury.
Rosenzweig ES, Salegio EA, Liang JJ, Weber JL, Weinholtz CA, Brock JH, Moseanko R, Hawbecker S, Pender R, Cruzen CL, Iaci JF, Caggiano AO, Blight AR, Haenzi B, Huie JR, Havton LA, Nout-Lomas YS, Fawcett JW, Ferguson AR, Beattie MS, Bresnahan JC, Tuszynski MH. Rosenzweig ES, et al. Among authors: caggiano ao. Nat Neurosci. 2019 Aug;22(8):1269-1275. doi: 10.1038/s41593-019-0424-1. Epub 2019 Jun 24. Nat Neurosci. 2019. PMID: 31235933 Free PMC article.
37 results